Olmesartan
Olmesartan is an ARB (angiotensin II receptor blocker), a medicine taken by mouth. The US label read, for Benicar tablets (olmesartan medoxomil), lists one use: treating high blood pressure in adults and in children six years of age and older. Benicar is the brand name on the label read.
Also called Benicar · Olmesartan medoxomil
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 321064; UNII 6M97XTV3HD. The label names the substance as olmesartan medoxomil, a prodrug that the label says is hydrolyzed to olmesartan, so UNII 6M97XTV3HD is the UNII of the medoxomil ester and is a broad match. MeSH descriptor D000068557 is Olmesartan Medoxomil, also a broad match. Class: Angiotensin 2 Receptor Blocker (FDA established pharmacologic class, RxClass). The label read is the Cosette Pharmaceuticals, Inc. label for Benicar (olmesartan medoxomil) tablets, application NDA021286, effective 2025-09-23 in openFDA; Drugs@FDA lists the application's sponsor as COSETTE. The older Benicar label with set id 5b6f8a18 (dated 2023-07-12), generic olmesartan labels and the Benicar HCT combination labels were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 13 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 13
- Phase 3 or 4
- 9
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|
| Phase 2 | 3 | 0 | 1 | 4 |
| Phase 3 | 5 | 0 | 1 | 6 |
| Phase 4 | 1 | 1 | 1 | 3 |
| All phases | 9 | 1 | 3 | 13 |
Conditions these trials study
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- Not reported
Classification codes
-
6M97XTV3HD -
D000068557
Claims and evidence
Context Adults for whom the US label of olmesartan (Benicar) lists an indication: hypertension
- Recipient
- Adult
- Population
- Adult patients described in the indications section of the label. The hypertension sentence also names children six years of age and older, who are recorded in a separate context.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the passage read states
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Adult patients with hypertension
- Excluded
- None stated
The US label of Benicar (olmesartan medoxomil) tablets, in the Cosette Pharmaceuticals, Inc. version dated 2025-09-23 in openFDA, lists the medicine for the treatment of hypertension in adults, to lower blood pressure (the same label sentence also names children six years of age and older, recorded separately).
Applies to Adult Adults for whom the US label of olmesartan (Benicar) lists an indication: hypertension
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2025-09-23
- Source state
- Current
- Version fingerprint
380c37611f59712fc5101ea575899a00a47645d1b8c2f1a05d5d9ec6c3edbd61- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250923.
- Retrieved
- Source effective date
- 2025-09-23
- Source state
- Current
- Version fingerprint
380c37611f59712fc5101ea575899a00a47645d1b8c2f1a05d5d9ec6c3edbd61- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Background openFDA Drugs@FDA record for application NDA021286 (BENICAR, sponsor COSETTE): product and sponsor
- Locator
- results[0].products[0].brand_name
- How it applies
- Drugs@FDA product listing for application NDA021286, which confirms the product the label belongs to.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
ada3a2c27b76f10d908badc757070fe0fffe28b6cfbafef3ceaac5819a15264f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short values are quoted. The raw record is committed in the atlas repository.
Context Children for whom the US label of olmesartan (Benicar) lists hypertension as an indication: children six years of age and older
- Recipient
- Child
- Population
- Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Label wording: children six years of age and older
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Children with hypertension (children six years of age and older)
- Excluded
- None stated
The US label of Benicar (olmesartan medoxomil) tablets, in the Cosette Pharmaceuticals, Inc. version dated 2025-09-23 in openFDA, lists the medicine for the treatment of hypertension in children six years of age and older, to lower blood pressure.
Applies to Child Children for whom the US label of olmesartan (Benicar) lists hypertension as an indication: children six years of age and older
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentence that names children in the hypertension indication, quoted in the research quote table.
- Retrieved
- Source effective date
- 2025-09-23
- Source state
- Current
- Version fingerprint
380c37611f59712fc5101ea575899a00a47645d1b8c2f1a05d5d9ec6c3edbd61- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250923.
- Retrieved
- Source effective date
- 2025-09-23
- Source state
- Current
- Version fingerprint
380c37611f59712fc5101ea575899a00a47645d1b8c2f1a05d5d9ec6c3edbd61- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
In newborns, infants and children 1
The US label of Benicar (olmesartan medoxomil) tablets, in the Cosette Pharmaceuticals, Inc. version dated 2025-09-23 in openFDA, lists the medicine for the treatment of hypertension in children six years of age and older, to lower blood pressure.
Applies to Child Children for whom the US label of olmesartan (Benicar) lists hypertension as an indication: children six years of age and older
Population, setting and follow-up
- Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Label wording: children six years of age and older
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentence that names children in the hypertension indication, quoted in the research quote table.
- Retrieved
- Source effective date
- 2025-09-23
- Source state
- Current
- Version fingerprint
380c37611f59712fc5101ea575899a00a47645d1b8c2f1a05d5d9ec6c3edbd61- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250923.
- Retrieved
- Source effective date
- 2025-09-23
- Source state
- Current
- Version fingerprint
380c37611f59712fc5101ea575899a00a47645d1b8c2f1a05d5d9ec6c3edbd61- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
AZOR
No label from the application holder was found in the openFDA label dataset for application NDA022100. This page does not show another labeler's label in its place.
BENICAR
No label from the application holder was found in the openFDA label dataset for application NDA021286. This page does not show another labeler's label in its place.
BENICAR HCT
No label from the application holder was found in the openFDA label dataset for application NDA021532. This page does not show another labeler's label in its place.
TRIBENZOR
No label from the application holder was found in the openFDA label dataset for application NDA200175. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists hypertension as an indication: Hypertension (high blood pressure)
Applies to Adult Adults for whom the US label of olmesartan (Benicar) lists an indication: hypertension
The US label of Benicar (olmesartan medoxomil) tablets, in the Cosette Pharmaceuticals, Inc. version dated 2025-09-23 in openFDA, lists the medicine for the treatment of hypertension in adults, to lower blood pressure (the same label sentence also names children six years of age and older, recorded separately).Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 4
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 13
Record details
- Record id
cardio:olmesartan- Content hash
d53eb236c363311721a4bcbed7ea56a28c82350486591a9a1fd5032238339f02